# High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza

> **NCT00298233** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 326 (actual)

## Conditions studied

- Influenza
- Avian Influenza
- Severe Influenza

## Interventions

- **DRUG:** Oseltamivir

## Key facts

- **NCT ID:** NCT00298233
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 326 (ACTUAL)
- **Last updated:** 2014-06-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00298233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00298233, "High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00298233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*